We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

48 hedge funds and large institutions have $4.36M invested in Relmada Therapeutics in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 20 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

160% more call options, than puts

Call options by funds: $340K | Put options by funds: $131K

13.18% less ownership

Funds ownership: 41.02% → 27.84% (-13%)

30% less funds holding

Funds holding: 69 → 48 (-21)

45% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 20

75% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 28

89% less capital invested

Capital invested by funds: $40.2M → $4.36M (-$35.9M)

Holders
48
Holders Change
-21
Holders Change %
-30.43%
% of All Funds
0.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
11
Reduced
20
Closed
28
Calls
$340K
Puts
$131K
Net Calls
+$209K
Net Calls Change
-$943K

Top Buyers

1
TCM
Tang Capital Management
California
+$366K
2
AI
AdvisorShares Investments
Maryland
+$345K
3
Renaissance Technologies
Renaissance Technologies
New York
+$338K
4
RA
Rosalind Advisors
Ontario, Canada
+$244K
5
UBS Group
UBS Group
Switzerland
+$216K

Top Sellers

1
DTC
Deep Track Capital
Connecticut
-$2.19M
2
PCM
Parsons Capital Management
Rhode Island
-$2.05M
3
Millennium Management
Millennium Management
New York
-$1.82M
4
VPC
Vestal Point Capital
New York
-$1.59M
5
OM
Opaleye Management
Massachusetts
-$1.56M
Name Holding Trade Value Shares
Change 		Change in
Stake
Franklin Resources
1
Franklin Resources
California
$677K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$653K – – –
Acadian Asset Management
3
Acadian Asset Management
Massachusetts
$636K +$101K +41,476 +3%
BlackRock
4
BlackRock
New York
$309K +$62.1K +25,446 +4%
PAI
5
Palo Alto Investors
California
$257K -$579K -237,254 -32%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$158K -$4.06K -1,664 -0.5%
Deutsche Bank
7
Deutsche Bank
Germany
$117K – – –
UBS Group
8
UBS Group
Switzerland
$112K +$216K +88,755 +70%
AI
9
AdvisorShares Investments
Maryland
$109K +$345K +141,540 +207%
Bank of America
10
Bank of America
North Carolina
$107K -$2 -1 -0%
TCM
11
Tang Capital Management
California
$104K +$366K +150,000 +295%
Two Sigma Advisers
12
Two Sigma Advisers
New York
$103K -$106K -43,600 -18%
Renaissance Technologies
13
Renaissance Technologies
New York
$85.5K +$338K +138,625 +535%
PCM
14
Parsons Capital Management
Rhode Island
$84.9K -$2.05M -839,359 -84%
RC
15
RBF Capital
California
$84.9K -$5.4K -2,213 -1%
Barclays
16
Barclays
United Kingdom
$75.9K – – –
Two Sigma Investments
17
Two Sigma Investments
New York
$66.3K -$155K -63,736 -33%
GCP
18
GSA Capital Partners
United Kingdom
$65K +$39.9K +16,361 +15%
State Street
19
State Street
Massachusetts
$55.5K +$18.3K +7,500 +8%
Group One Trading
20
Group One Trading
Illinois
$53.1K +$7.66K +3,142 +3%
MOS
21
MGO One Seven
Ohio
$52K – – –
RA
22
Rosalind Advisors
Ontario, Canada
$52K +$244K +100,000 New
Northern Trust
23
Northern Trust
Illinois
$43.8K +$23.3K +9,566 +13%
BCM
24
Bridgeway Capital Management
Texas
$37.8K -$265K -108,477 -60%
Citigroup
25
Citigroup
New York
$32.7K -$5 -2 -0%
1
2 3 4

RLMD Hedge Fund Activity: Q4 2024 in Review

48 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q4 2024, worth a combined $4.36M — down 89% from $40.2M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of RLMD and 7 opened new positions — a net loss of 21 holders — while 20 trimmed existing stakes and 11 added.

The largest buyer was Tang Capital Management, adding an estimated $366K. The largest seller was Deep Track Capital, exiting entirely with an estimated $2.19M sold.

  • 48 institutional investors held Relmada Therapeutics (RLMD) as of Q4 2024, down from 69 in Q3 2024.
  • Funds reported $4.36M of Relmada Therapeutics stock for Q4 2024, down 89% quarter-over-quarter.
  • 7 funds opened new Relmada Therapeutics positions in Q4 2024 and 28 closed out, a net change of -21 holders.
  • The largest Relmada Therapeutics buyer in Q4 2024 was Tang Capital Management, an estimated $366K added.
  • The largest Relmada Therapeutics seller in Q4 2024 was Deep Track Capital, an estimated $2.19M sold.

Based on aggregated 13F filings for Q4 2024.